Cargando…

A previously treated severe haemophilia A patient developed high-titre inhibitor after vaccinations

The factor VIII (FVIII)-neutralizing antibody (inhibitor) seen in 25%–30% of patients with severe haemophilia A (SHA). Vaccination is a non-genetic risk factor of inhibitor development as ‘danger signal’ which may provide a pro-inflammatory microenvironment to increase FVIII immunogenicity. We repor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Zekun, Chen, Zhenping, Cheng, Xiaoling, Wu, Xinyi, Li, Gang, Zhen, Yingzi, Poon, Man-Chiu, Wu, Runhui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338642/ https://www.ncbi.nlm.nih.gov/pubmed/32627611 http://dx.doi.org/10.1177/2058738420934618

Ejemplares similares

Low‐dose immune tolerance induction for children with hemophilia A with poor‐risk high‐titer inhibitors: A pilot study in China
por: Li, Zekun, et al.
Publicado: (2019)

Low‐dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors
por: Li, Zekun, et al.
Publicado: (2021)

Individualised prophylaxis based on personalised target trough FVIII level optimised clinical outcomes in paediatric patients with severe haemophilia A
por: Huang, Kun, et al.
Publicado: (2022)

Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A
por: Chen, Zhenping, et al.
Publicado: (2021)

PK‐tailored tertiary prophylaxis in patients with severe hemophilia A at Beijing Children's Hospital
por: Li, Peijing, et al.
Publicado: (2019)

F8 gene mutation spectrum in severe hemophilia A with inhibitors: A large cohort data analysis from a single center in China
por: Sun, Jie, et al.
Publicado: (2022)

Enhanced pharmacokinetics and reduced bleeds in boys with hemophilia A after switching to Kovaltry from other standard half‐life factor VIII concentrates
por: Huang, Kun, et al.
Publicado: (2022)

Low‐dose immune tolerance induction in children with severe hemophilia A with high‐titer inhibitors: Type of factor 8 mutation and outcomes
por: Sun, Jie, et al.
Publicado: (2022)

Exploration of the minimum necessary FVIII level at different physical activity levels in pediatric patients with hemophilia A
por: Ai, Di, et al.
Publicado: (2022)

F9 mutations causing deletions beyond the serine protease domain confer higher risk for inhibitor development in hemophilia B
por: Liu, Guoqing, et al.
Publicado: (2023)

Rehabilitation management of a triceps surae muscle injury in a young male with haemophilia A and high-titre inhibitors
por: Frizziero, Antonio, et al.
Publicado: (2021)

Real-world experience of emicizumab prophylaxis in young children with hemophilia A: retrospective data from China
por: Liu, Guoqing, et al.
Publicado: (2022)

Pharmacokinetics and complementary evaluation system-based guidance on prophylaxis of paediatric patients with haemophilia A in China with Kovaltry: protocol of the LEAP study
por: Kun, Huang, et al.
Publicado: (2021)

Long-term treatment course of a patient with mild haemophilia A who developed a high titre factor VIII inhibitor
por: Iioka, F, et al.
Publicado: (2014)

Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial
por: Yaish, Hassan, et al.
Publicado: (2019)

Development and desensitization therapy of high-response factor VIII inhibitors with severe allergic reaction in a moderate hemophilia A patient
por: Liu, Guoqing, et al.
Publicado: (2021)

Low‐dose immune tolerance induction therapy in children of Arab descent with severe haemophilia A, high inhibitor titres and poor prognostic factors for immune tolerance induction treatment success
por: Elalfy, Mohsen, et al.
Publicado: (2021)

Central venous access devices implantation in children with severe hemophilia a: data from the children comprehensive care center of China
por: Xu, Qian, et al.
Publicado: (2023)

Efficacy and safety of eltrombopag in the treatment of severe chronic immune thrombocytopenia in children of China: A single-center observational study
por: Cheng, Xiaoling, et al.
Publicado: (2019)

Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A
por: Auerswald, Guenter, et al.
Publicado: (2012)

Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study
por: Liesner, Ri J., et al.
Publicado: (2021)

PROTECT VIII Kids: BAY 94‐9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A
por: Santagostino, Elena, et al.
Publicado: (2020)

Neutralizing antibody titres in SARS-CoV-2 infections
por: Lau, Eric H. Y., et al.
Publicado: (2021)

A novel mutation in GP1BA gene in a family with autosomal dominant Bernard Soulier syndrome variant: A case report
por: Ma, Jingyao, et al.
Publicado: (2021)

Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult‐to‐treat patients
por: Ljung, Rolf, et al.
Publicado: (2018)

Phase 4 Safety and Efficacy Study of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients With Severe/Moderately Severe Hemophilia A
por: Zhao, Yongqiang, et al.
Publicado: (2021)

Inhibitor development in previously untreated patients with severe haemophilia: A comparison of included patients and outcomes between a clinical study and a registry‐based study
por: Jonker, Carla J., et al.
Publicado: (2020)

Hæmophilia
Publicado: (1905)

Hæmophilia
por: Ruggles, S. D.
Publicado: (1902)

Hæmophilia
por: Porter, Charles A.
Publicado: (1900)

European principles of inhibitor management in patients with haemophilia
por: Giangrande, P. L. F., et al.
Publicado: (2018)

Lupus pneumonitis presenting with high titre of anti‐Ro antibody
por: Chen, Mei‐Chuan, et al.
Publicado: (2017)

Zero incidence of factor VIII inhibitors and successful haemostatic response in previously factor VIII‐treated patients with haemophilia A switching to turoctocog alfa in a noninterventional study
por: Escuriola Ettingshausen, Carmen, et al.
Publicado: (2021)

Performance of a clinical risk prediction model for inhibitor formation in severe haemophilia A
por: Hassan, Shermarke, et al.
Publicado: (2021)

The cost of severe haemophilia in Europe: the CHESS study
por: O’Hara, Jamie, et al.
Publicado: (2017)

Titres StockShots: Video History
Publicado: (2016)

Switching treatments in haemophilia: is there a risk of inhibitor development?
por: Santagostino, Elena, et al.
Publicado: (2015)

The evolution of factor VIIa in the treatment of bleeding in haemophilia with inhibitors
por: Meeks, Shannon L., et al.
Publicado: (2019)

Legg on Hæmophilia
Publicado: (1873)

Malarious Hæmophilia
Publicado: (1890)

Cannot write session to /tmp/vufind_sessions/sess_c2jojmjsvmgldqjn7ma81o4s74